다발성 경화증 시장 규모, 점유율, 성장 분석 : 약제 클래스별, 진단별, 투여 경로별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Multiple Sclerosis Market size was valued at USD 26.64 Billion in 2024 and is poised to grow from USD 27.25 Billion in 2025 to USD 32.69 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global multiple sclerosis (MS) landscape showcases a growing demand for innovative treatments, driven by the condition's immune-mediated nature that disrupts the central nervous system. Key characteristics, such as demyelination and neuroaxonal loss, highlight the urgent need for effective therapies. Monoclonal antibodies, including humanized variants, are at the forefront of treatment development, with numerous clinical trials aimed at discovering new drugs. The rising prevalence of MS emphasizes the significance of diagnosis and therapy, prompting government support for treatment initiatives. To fuel this market, major players are increasingly focusing on research and development, while collaborative efforts between pharmaceutical companies and academic institutions are further stimulating advancements in MS therapeutics, leading to a burgeoning drug industry focused on addressing diverse symptoms impacting patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The growing prevalence of multiple sclerosis significantly fuels the expansion of the market. This neurological condition presents in various forms, including relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), each demonstrating a notable incidence that influences market dynamics. As the rates of these different types continue to rise, the demand for effective treatments and advanced therapies increases, driving innovation and investment within the sector. This heightened awareness and the search for better management options contribute to the overall growth trajectory of the global multiple sclerosis market.

Restraints in the Global Multiple Sclerosis Market

The growth of the global multiple sclerosis market may be hindered by several factors. The high costs associated with treating the disease can restrict accessibility and limit market expansion. Additionally, developing countries may struggle with insufficient healthcare infrastructure and a lack of qualified professionals, further complicating treatment availability. The repercussions of recent health crises have also led to a decline in clinical visits, which can impact patient engagement and care continuity. Moreover, widespread gaps in awareness surrounding multiple sclerosis contribute to challenges in patient education and diagnosis, ultimately acting as constraints on the overall growth potential of the market.

Market Trends of the Global Multiple Sclerosis Market

The Global Multiple Sclerosis market is witnessing a notable trend driven by substantial investments in research and development. Pharmaceutical companies are increasingly focused on advancing innovative treatment modalities to address this complex disease, fostering a competitive landscape characterized by robust clinical trials and collaborations with research institutions. The emergence of novel therapies, including selective receptor antagonists, is indicative of a thriving pipeline that promises to enhance patient outcomes. As various stakeholders actively engage in expanding their portfolios, this heightened R&D activity is poised to not only introduce groundbreaking therapies but also catalyze broader market expansion, ultimately reshaping the future of multiple sclerosis management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Multiple Sclerosis Market Size & CAGR (2026-2033)

• North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
• Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TG Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations